EVERCYTE GMBH

Their core work

Evercyte is a Vienna-based biotech SME specializing in immortalized human cell lines and in vitro cell-based models for safety testing and pharmacological research. They provide standardized cell technologies that enable chemical and drug safety assessment without animal testing. Their work spans mammalian cell systems engineering, placental barrier models, and bioprinting-based tissue constructs for reproductive and fetal health research.

What they specialise in

How they've shifted over time

Evercyte's trajectory shows a clear shift from general mammalian cell engineering toward applied safety testing and ultimately into a specialized niche of reproductive health. Their earliest project (eCHO Systems, 2015) was about optimizing CHO cell production — a biomanufacturing workhorse. By 2017-2021, they moved into animal-free chemical safety assessment (in3), and their most recent project (LIFESAVER, 2021-2025) narrows further into drug safety during pregnancy using placental models, bioprinting, and digital twin technology.

Evercyte is moving from general cell biology services toward highly specialized reproductive safety models combining bioprinting and digital twin technology — a niche with growing regulatory demand.

How they like to work

Evercyte consistently joins consortia as a participant or third party, never leading as coordinator — a pattern typical of specialist SMEs that contribute specific technical capabilities (cell lines, in vitro assays) rather than managing large projects. With 50 unique partners across 18 countries from just 3 projects, they operate within large, diverse research consortia. This suggests they are sought after as a reliable technology provider that integrates well into multidisciplinary teams.

Despite only three projects, Evercyte has built a remarkably broad network of 50 partners spanning 18 countries, reflecting participation in large EU training networks and research consortia. Their geographic footprint is pan-European with no single dominant partner country.

What sets them apart

Evercyte occupies a rare niche at the intersection of immortalized cell technology, alternative-to-animal testing, and reproductive health — three areas with strong regulatory tailwinds in the EU. Few SMEs can supply validated human cell models specifically designed for placental barrier and fetal exposure studies. For consortium builders, they bring production-ready in vitro tools that directly address the EU's push to replace animal testing under REACH and new pharmacovigilance requirements.

Highlights from their portfolio

• LIFESAVER
  Their largest funded project (EUR 427,862) tackling the underserved area of drug safety during pregnancy, combining bioprinting, placental models, and digital twin technology.
• in3
  An integrated approach to animal-free safety assessment for chemicals and nanomaterials — directly aligned with EU regulatory direction on replacing animal testing.
• eCHO Systems
  An MSCA training network on CHO cell optimization, showing Evercyte's roots in mammalian cell systems before specializing further.